ABSTRACT OBJECTIVE: Type 1 diabetes and multiple sclerosis (MS) are typical autoimmune diseases in children and young adults. We assessed the co-occurrence of type 1 diabetes and MS by estimating the relative risk for MS in a pediatric and adolescent diabetes population and looked for possible influencing factors.
INTRODUCTION
Type 1 diabetes and Multiple Sclerosis (MS) are organ specific inflammatory diseases, which result from an autoimmune attack against either pancreatic ß-cells or central nervous system; a combined appearance has been described repeatedly (1) (2) (3) . For children and adolescents below the age of 21 the prevalence for type 1 diabetes in Germany and Austria is about 19.4 per 100,000 and for MS it ranges from 7 to 10 /100,000 (4) (5) (6) . A Danish cohort study revealed a three times higher risk for patients with type 1 diabetes to develop MS (7) . Further, an Italian study from Sardinia could show an even five times increased risk for MS patients to get type 1 diabetes (8; 9 ). An American study on female adults with diabetes manifestation before the age of 21 yielded an up to 20 times higher risk in the prevalence of MS (10) .
These findings support the hypothesis of clustering between type 1 diabetes and MS.
The pathogenesis behind this association is still unclear, but T cell cross reactivity was discussed as well as shared disease associations due to the HLA-DRB1-DQB1 gen loci (8; 11) . The geographical appearance of diabetes and multiple sclerosis are quite similar, therefore, besides a genetic component environmental factors might be relevant in both diseases (10) . Ponsonby et al. speculated that the higher incidence of diabetes and multiple sclerosis might depend on the month of birth and the vitamin D exposition during pregnancy (12) .
Most previous observations on co-occurrence of the two autoimmune diseases have been based on case reports, patient series or smaller epidemiologic studies limited by a modest number of patients with MS and type 1 diabetes. Therefore, the reported co-occurrence of type 1 diabetes and MS needs further confirmation. Most studies investigated MS population and searched for type 1 diabetes, while we investigated a 15).
Statistical methods:
The standardized prevalence ratio, that is the ratio of observed to expected numbers of patients with MS in the diabetes cohort, served as a measure of relative risk (RR).
The expected numbers of patients with MS were calculated as the sum of agespecific person at risk in the type 1 diabetes cohort multiplied by corresponding national age-specific MS prevalence rates available from the Mid-European and German MS pediatric and adult registers (5; 14; 15). Ninety-five percent confidence intervals (CI`s) for the RR`s were estimated from the Wald test, assuming a Poisson distribution of the observed cases.
Descriptive statistics (mean, SD, percentage) were calculated. Multivariable linear mixed regression models were applied to assess the effect of possible confounders on the prevalence of MS within the diabetes population. Age, sex, diabetes duration, migration background, therapy regime and daily insulin dose were included as fixed independent effects. Dependent variables were month of birth, BMI-SDS, thyroid, celiac disease and diabetes specific antibodies. Asymmetrical confidence intervals for fixed-effect parameters were constructed, and standardized coefficients were used to assess the relative importance of independent confounders. Estimates of regression coefficients (and standard errors) and respective Wald and F-tests were used to assess the relative importance of influencing factors. P-value less than 0.05 were considered as statistically significant.
RESULTS

Relative risk
We Results of multivariable linear regression models showed that BMI or BMI SDS, thyroid or celiac disease specific antibodies were not different between the type 1 diabetes and type 1 diabetes-MS groups. After separation for sex, male patients with thyroid specific antibodies had an elevated probability to develop MS that was close to a p-value of 0.05 (ß -0.18, p= 0.053).
Looking at the distribution of month of birth within the type 1 diabetes-MS population there were two peaks in June and August and a lower birth rate in April. Splitting the month of birth based on the sun exposition during pregnancy, we divided the population in groups of lower vitamin D exposure from May to October and higher exposure from November to April. 14 patients were born in the lower exposure month, whereas 5 patients were born in the vitamin D higher exposure. In contrast, there was an almost equal distribution of month of birth in the MS (16) and the total type 1 diabetes population within DPV.
Discussion
We used a large database of pediatric and adolescent type 1 diabetes patients to analyze the relative risk of MS co-occurrence. The DPV database includes about 98% of pediatric diabetes population in Germany and Austria below the age of 21. In children and adolescents the relative risk for MS in type 1 diabetes was estimated 3 to almost 5 times higher in comparison to the healthy population. Our findings are comparable with data from Sardinia in which 2 to 5-fold higher prevalence of type 1 diabetes were observed in adult patients with MS, compared with the general population (8;9). A Danish study using three population based disease-registers showed a 3-fold increased risk in adult type 1 diabetes patients for the development of MS (7).
In this diabetes population, sex distribution was comparable between type 1 diabetes and type 1 diabetes-MS patients. There was a trend for a higher number of males with co-occurrence of type 1 diabetes -MS as expected from MS data in pubertal and postpubertal population (14) . However, due the low number of MS patients this did not reach statistical significance. The diabetic patients who developed MS did not differ from the diabetes only population with respect to age at diabetes onset and insulin dose. BMI-SDS was significantly higher but whether this was biased by higher age and possible MS relapse treatment with glucocorticoid pulses could only be speculated.
The pathomechanism behind the co-occurrence of type 1 diabetes and MS is quite unclear. MS and type 1 diabetes are associated with several immune abnormalities directed against different autoantigens. Predisposing common HLA haplotype in patients with type 1 diabetes-MS has not been found in adult studies (17; 18) . Both diseases are considered to be T-cell-mediated, as characterized by decreased T-cell suppressor activity and autoantigene-specific T-helper cell response and the presence of numerous autoantibodies (11) . However, a polymorphism in the T-cell receptor did not influence the susceptibility to type 1 diabetes and MS in the Sardinian population (19) . IL-2 receptor polymorphism was discussed to reflect the existence of a heterogeneous association between type 1 diabetes and MS, suggesting different immunopathological mechanisms of IL2RA in the two diseases (20; 21) . The higher rate of thyroid specific antibodies in male type 1 diabetes-MS patients in this population might fit to the hypothesis of autoreactive T-cells (10) .
The underlying mechanisms may involve both genetic and environmental causes.
Therefore we looked for possible factors like age at diabetes manifestation, rate of diabetes specific antibodies, thyroid specific antibodies and celiac disease specific antibodies. None of these factors turned out to be significantly different from the type One limitation of this analysis from the diabetes-centered database is that MS-related information is not documented systematically and so we could not give detailed information on family history, number of relapses, and type of MS (e.g. type of progression) under certain current medication that would be of interest for anyone, dealing with MS patients. In some patients we did not get the whole information of patient related data (e.g. age at onset of MS). Furthermore, the elevated relative risk for the co-occurrence could only be estimation. On the one hand, age distribution within the type 1 diabetes and type 1 diabetes-MS population is not similar and a correction for age was not performed. On the other hand, data might be biased, since it is possible that patients with type 1 diabetes are more likely to be diagnosed with MS faster than the general population and cases of MS in the MS registry could be underreported. In addition, the number of type 1 diabetes-MS patients is small. Data on month of birth distribution are therefore speculative and need proof on a larger population. In terms of month of birth a subdivision of the whole diabetes population into gender or ethnicity and a comparison with patients with MS and type 1 diabetes would be of interest. However, the number of patients with co-occurrence of the two diseases is too small for analysis in subgroups. The strength of the study is the multicenter approach and the long-term standardized follow-up of a large population of children and adolescents with type 1 diabetes.
In conclusion, we found about a 3 to 5-times higher rate of patients with the cooccurrence of type 1 diabetes and MS within a pediatric diabetes population. This might be due to a higher common susceptibility to multiple autoimmune diseases also if multiple sclerosis and autoimmune diabetes are not classified under one of the established autoimmune syndromes. We also found that the strong predominance of female gender in MS patients was lower in this type 1 diabetes-MS cohort and type 1 diabetes-MS males had an almost significant higher rate of additional thyroid specific antibodies. Beside genetic, environmental factors like vitamin D and its levels during early pregnancy and immigration background might be a modulator of autoimmune disease. These specific effects found only in the type 1 diabetes-MS group draw attention to a subtype of immune disease that results in combined autoimmunity against endocrine and neuronal antigens. To follow this interesting topic, prospective documentation of detailed disease related data of type 1 diabetes-MS patients is 
